Nice post Hingdog.
If I remember correctly, in response to the superbug problem, the FDA were extending the patent period for companies developing treatments for the aforementioned! No doubt would add additional value to any company succesful in finding a treatment MRSA , staph etc.
Ann: Botanix Initiates BTX 1702 Rosacea Study, page-18
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.3¢ |
Change
0.003(0.76%) |
Mkt cap ! $531.6M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 34.5¢ | 33.0¢ | $1.339M | 3.967M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 52 | 1203322 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 60231 | 12 |
View Market Depth
| Last trade - 14.09pm 18/06/2024 (20 minute delay) ? |
|
|||||
|
Last
33.5¢ |
Change
0.003 ( 0.18 %) |
||||
| Open | High | Low | Volume | ||
| 33.0¢ | 34.5¢ | 33.0¢ | 1775904 | ||
| Last updated 14.30pm 18/06/2024 ? | |||||
| BOT (ASX) Chart |